Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders

J Hepatol. 2006 Feb;44(2):310-6. doi: 10.1016/j.jhep.2005.10.015. Epub 2005 Nov 14.

Abstract

Background/aims: We aimed to characterize by echo-color-Doppler the splanchnic hemodynamics of patients good and poor responders to primary prophylaxis with nadolol.

Methods: Thirty cirrhotic patients (Child-score 7.0+/-1.8) with medium/large esophageal varices without previous bleedings were consecutively enrolled. At inclusion and after 3 months of treatment with nadolol, they underwent a splanchnic echo-color-Doppler study and a measurement of hepatic venous pressure gradient (HVPG).

Results: Nadolol (60+/-36 mg/day; range 20-160) induced a significant reduction of HVPG (16.6+/-6.1 vs. 19.4+/-4.6 mmHg, P < 0.0001). 13 patients (43.3%) were hemodynamic responders. Responders and Poor-responders had similar baseline clinical characteristics. Poor-responders at baseline were characterized by lower impedance indexes in superior mesenteric artery (SMA) (PI 2.29+/-0.45 vs. 2.74+/-0.46; P = 0.01; RI 0.83+/-0.04 vs. 0.86+/-0.03; P = 0.02), hepatic artery (HA) (PI 1.41+/-0.19 vs. 1.79+/-0.48; P = 0.03; RI 0.71+/-0.05 vs. 0.80+/-0.07; P = 0.02), and splenic artery (SA) (PI 1.18+/-0.27 vs. 1.73+/-0.40; P = 0.01; RI 0.66+/-0.07 vs. 0.73+/-0.09; P = 0.02), and by higher mean flow velocity of HA (52.6+/-21.6 vs. 26.5+/-9.5 cm/s; P = 0.02) and SMA (49.7+/-14.5 vs. 33.9+/-13.1 cm/s; P = 0.06).

Conclusions: Cirrhotic patients poor-responders to nadolol show a pronounced arterial splanchnic vasodilatation at a baseline echo-color-Doppler study. This can be considered a non-invasive clue for the a priori identification of this subgroup of patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Blood Flow Velocity / drug effects
  • Blood Flow Velocity / physiology
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Hepatic Veins / diagnostic imaging
  • Hepatic Veins / physiopathology
  • Humans
  • Hypertension, Portal / etiology
  • Hypertension, Portal / physiopathology
  • Hypertension, Portal / prevention & control*
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / diagnostic imaging
  • Liver Cirrhosis / physiopathology*
  • Male
  • Mesenteric Arteries / diagnostic imaging
  • Mesenteric Arteries / physiopathology
  • Middle Aged
  • Nadolol / therapeutic use*
  • Primary Prevention / methods*
  • Prospective Studies
  • Splanchnic Circulation / drug effects
  • Splanchnic Circulation / physiology*
  • Treatment Outcome
  • Ultrasonography, Doppler, Duplex*
  • Vasoconstriction / drug effects

Substances

  • Adrenergic beta-Antagonists
  • Nadolol